advertisement
Baba Ramdev-founded Patanjali Ayurved Ltd has become India’s second biggest consumer goods maker behind Hindustan Unilever Ltd, riding on the success of its lower-priced ayurvedic products.
The company reported higher sales than rivals like ITC Ltd (FMCG segment) and Godrej Consumer Products Ltd in the year ended March. The growth was driven by key products like cow’s ghee, toothpaste and herbal soaps and shampoos. The company expanded into newer categories, taking its yearly revenue to Rs 10,561 crore.
Patanjali has positioned itself in the entire FMCG space as “very Indian and rural-oriented”, said Dhanraj Bhagat, retail partner at consultancy Grant Thornton India LLP. Competitive prices make its products immensely popular, he said. Its revenue grew at a faster pace, even though its distribution reach is nearly a fifth of the average of its rivals’.
Ajay Thakur, research analyst at Anand Rathi Securities, pegged HUL’s distribution reach at 5.6 million outlets, ITC’s at 4.5 million, Dabur’s at 5 million, Colgate Palmolive’s at 5 million outlets, and Marico’s at 4-4.5 million outlets.
Rivals added ayurvedic or herbal products to their portfolio to tap the demand created by the maker of Dantakanti toothpaste and Patanjali desi cow’s ghee, the largest contributor to its revenue. Here are Patanjali’s top five products and how it compares with rivals…
In the organised branded ghee market, Patanjali is a direct rival to Amul. Branded ghee accounts for about 44 percent of volumes in the overall market, according to market researcher Kantar Worldpanel.
Patanjali is the only brand that seems to have a good presence across zones, Kantar Worldpanel said. It has the highest volume share, followed by Amul, Krishna, Milma, Nandini and BRB, Kantar said. Patanjali and Amul are at nearly the same level in terms of penetration, it said.
The maker of Dantkanti toothpaste earned a revenue of Rs 940 crore from the segment. The company said its share in market stood at 14 percent at the end of March.
Rivals include market leader Colgate Palmolive India Ltd and Dabur India Ltd. Colgate Palmolive saw its share fall to 55.6 percent in 2016 compared to 57.4 percent in the previous year, according to its investor presentation.
Dabur India, maker of Dabur Red and Meswak brands, said in its earnings conference call that its share in the herbal and ayurvedic toothpaste market rose 1 percentage point in the year ended March, amid consumers’ growing preference for such products. Both Colgate Palmolive and Dabur India did not comment on their strategy to counter Patanjali’s challenge.
Patanjali earned Rs 870 crore revenue from ayurvedic medicines, nearly four times compared to its direct rival Dabur India.
Patanjali has captured the lower end of the market but has not been able to penetrate the premium market, said Prashant Agarwal, joint managing director of Wazir Advisors, a retail and brand consultancy firm. Hindustan Unilever is the market leader with a 45 percent share in shampoos.
India’s largest consumer goods maker earned Rs 16,304 crore from the personal care segment, which includes shampoo and soap brands like Dove, Sunsilk, Tresemme and Lux, and skincare products like Fair & Lovely and Ponds cream.
HUL said its ‘naturals’ segment in personal care is growing fast, tracking the trend in several parts of the world. The Anglo-Dutch consumer goods maker relaunched its Lever Ayush brand and also acquired Indulekha, a premium hair care brand. HUL also launched Tresseme Botanique, Fair & Lovely Ayurveda, Clinic Plus Ayurveda Care and Citra – a specialist naturals brand.
Patanjali’s herbal soap segment mopped up a revenue of Rs 574 crore. Other than toothpaste and shampoo, Patanjali has not challenged existing players in the rest of the personal care market as its other products have not yet been able to gain acceptance, Agarwal said.
Patanjali also makes other food and non-food consumer goods like mustard oil, flour, biscuits, honey, washing powder, aloe vera juice, aloe vera gel, skincare, chyawanprash and health drinks.
(This article was originally published on BloombergQuint. This is an opinion piece and the views expressed above are the author’s own. The Quint neither endorses nor is responsible for the same. You can follow her on Twitter @sharleendsouza. )
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)